Synthesis and Antiviral Bioactivity of Novel 3‑((2-((1<i>E</i>,4<i>E</i>)‑3-Oxo-5-arylpenta-1,4-dien-1-yl)phenoxy)methyl)-4(3<i>H</i>)‑quinazolinone Derivatives

A series of novel 3-((2-((1<i>E</i>,4<i>E</i>)-3-oxo-5-arylpenta-1,4-dien-1-yl)­phenoxy)­methyl)-4­(3<i>H</i>)-quinazolinone derivatives were designed and synthesized. Antiviral bioassays indicated that a few of the compounds exhibited higher antiviral activities against tobacco mosaic virus (TMV) in vivo than the commercial agent ningnanmycin. In particular, compounds <b>A</b>_<b>5</b>, <b>A</b>_<b>12</b>, <b>A</b>_<b>25</b>, and <b>A</b>_<b>27</b> possessed appreciable curative bioactivities on TMV in vivo, with 50% effective concentration values ranging from 132.25 to 156.10 μg/mL. These values are superior to that of ningnanmycin (281.22 μg/mL) and suggest that novel 4­(3<i>H</i>)-quinazolinone derivatives containing 1,4-pentadien-3-one moiety can effectively control TMV. Evaluation of the antiviral properties in field studies and the mechanisms underlying the enhanced antiviral activities of these derivatives are an interesting topic for future investigation